|
Marcus' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
Rezolute’s phase 3 tumor hyperinsulinism trial met its main goal, while two genetically backed heart drugs failed and Regeneron reported POTS results.
The top 10 stories from Fri Nov 13, 2026 06:49 AM to Mon Nov 16, 2026 06:50 AM
Generated November 16, 2026 at 6:50 AM
|
|
|
#1 Deaths, failed trials and other recent setbacks in the autoimmune space Published 2026-11-16 Novartis, Bristol Myers Squibb, argenx and other drugmakers have faced autoimmune-program setbacks, including discontinued assets, strategic pauses and safety concerns. Covered by: biospace.com |
#2 The future of heart drug research in the wake of study setbacks Published 2026-11-13 Two heart disease drugs backed by genetic research failed to show clinical benefit, raising questions about genetics’ role in cardiovascular drug development. Covered by: statnews.com |
#3 US FDA, Sponsors Still Not Aligned On Streamlined Preclinical Programs Published 2026-11-13 The FDA is discussing how reviewers across divisions can apply a consistent approach to alternative preclinical development programs, while sponsors remain misaligned with the agency. Covered by: insights.citeline.com |
#4 Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filing Published 2026-11-13 Regeneron reported that 450 mg of baloncibart reduced heart rate by an average of 11.4 beats per minute in a mid-stage POTS study; Kyverna completed a CAR-T filing. Covered by: endpoints.news |
#5 Preventive Medicine’s Bottleneck Is Not Science – It’s Economics Published 2026-11-13 Preventive gene therapies are advancing rapidly and drawing major investment, but their adoption may be constrained by economics rather than scientific progress. Covered by: insights.citeline.com |
#6 Cellectis could cut 70% of workforce in shift to in vivo therapies Published 2026-11-13 Cellectis may cut about 160 jobs, or 70% of its workforce, and has halted enrollment in two CAR T programs while prioritizing in vivo therapy trials. Covered by: biospace.com |
#7 Inhibrx Reports Third Quarter 2026 Financial Results Published 2026-11-13 Inhibrx Biosciences reported third-quarter 2026 financial results and said it has two programs in ongoing clinical trials. Covered by: prnewswire.com |
#8 Faster Clinical Trials Act’s Bipartisan Backing Could Bolster US FDA User Fee Package Bid Published 2026-11-13 Bipartisan support for the Faster Clinical Trials Act could strengthen efforts to include it in the FDA user fee package; the bill proposes a hub-and-spoke clinical research system. Covered by: insights.citeline.com |
#9 Rezolute gets an uplift from phase 3 tumor hyperinsulinism win ahead of FDA meeting Published 2026-11-13 Rezolute said its phase 3 trial of ersodetug for tumor hyperinsulinism met its primary endpoint, ahead of a potential FDA filing for another indication. Covered by: fiercebiotech.com, insights.citeline.com |
#10 Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026 Published 2026-11-14 Servier will present up to four years of follow-up data from its Phase 2 FIREFLY-1 study of tovorafenib in children with relapsed or refractory BRAF-altered low-grade glioma at SNO 2026. Covered by: prnewswire.com |